Lexicon Pharma (LXRX) Tops Q3 EPS by 7c, Miss on Revenues
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.16 --0%
Revenue Growth %: -86.1%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
CRWS, MEI, PODC, More
Revenue Growth %: -86.1%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
CRWS, MEI, PODC, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.29), $0.07 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $26.94 million versus the consensus estimate of $27.96 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- MSCI acquires First Street for $120M to expand climate risk data
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
